ArticleNucleic acids research2026
ASF1B promotes erythropoiesis by regulating the establishment and enrichment of H3.3 nucleosomes.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Histone chaperone ASF1B is largely known to be functionally correlated with cell proliferation and cell cycle. We found that the expression of ASF1B was abundant together with histone variant H3.3 during in mouse fetal liver cells. However, the mechanism underlying this coordination is still unclear. HIRA, a H3.3 specific chaperone, was dispensable in fetal hematopoiesis. In contrast, we found that ASF1B predominantly regulated H3.3 encoding genes and erythroid genes, whereas ASF1A served a compensatory function. Notably, ASF1B occupied >70% of H3.3 nucleosomes and determined H3.3 enrichment at erythroid gene promoters and enhancers. However, loss of ASF1B de-repressed the expression of embryonic/fetal globin genes by altering enrichment of H3.3 and erythroid transcription factors as well as chromatin accessibility. The regulatory pathway of ASF1B in H3.3 enrichment involved the recruitment of chromatin remodeler BRG1 and accumulation of H3K27ac in active chromatin. In summary, ASF1B plays a crucial role in enrichment of H3.3 nucleosomes and establishment of the chromatin environment to affect erythroid gene expression, highlighting the therapeutic potential of ASF1B in targeting erythrocyte disorders, such as β-globin hemoglobinopathies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.